Compare HYPR & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | PMVP |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 81.3M |
| IPO Year | 2021 | 2020 |
| Metric | HYPR | PMVP |
|---|---|---|
| Price | $0.86 | $1.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.03 | ★ $4.20 |
| AVG Volume (30 Days) | ★ 875.4K | 718.8K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $49.18 | N/A |
| Revenue Next Year | $29.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.75 | $1.02 |
| 52 Week High | $2.22 | $1.91 |
| Indicator | HYPR | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 42.54 |
| Support Level | $0.75 | $1.32 |
| Resistance Level | $1.39 | $1.35 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 35.68 | 8.73 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.